In a breakthrough in migraine treatment, the Phase 2 results of the clinical trials of AMG 334 drug by Amgen, Inc. (NASDAQ:AMGN) has been successful. Competing with the existing migraine drugs, the monthly rates of migraine attacks were comparably less when using this medication. According to the company, the AMG 334 drug lowered the chance of migraines by 3.4 days as compared to the 2.28-day monthly migraine drop that the existing drugs offer.
Amgen released the findings of their study at the 17th Congress of the International Headache Society that was held in Valencia, Spain.
Even in the headache category, the latest drug offered 3.54 off days per month than the 2.39 days by the other drugs. The monthly medicine usage rates were also lesser at 1.64 days than the 0.69 days that existing drugs offered. The company is planning to undergo the Phase 3 trials in the second half of 2015.
CGRP treatments are the future of curing migraine, and the drug is an essential addition to the category. The company feels that they can target a large group of patients through this treatment in a cost-effective manner.
The CGRP treatment aims at helping trigger off migraine by constriction in the blood vessels and more patients respond to these than the traditional treatments. The medical experts have been debating the efficacy of these treatments even though the results have been positive so far. Companies like Amgen are confident of achieving a breakthrough in the domain and help in developing and marketing drugs that can help more patients fight against the migraine symptoms. Scientists are meanwhile, busy in discovering the mechanism to reverse the effects of brain ailments.
Similar efforts are also being pursued by Alder Biopharmaceuticals Inc (NASDAQ:ALDR) with the ALD403 drug that is underway Phase 2 study. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) is also in the race, along with Arteaus that is working on an Eli Lilly and Co (NYSE:LLY) drug. Bristol-Myers Squibb Co (NYSE:BMY) is also conducting trials of a BMS-927711 drug that can offer AMG 334 tough competition in future. However, Merck & Co., Inc. (NYSE:MRK) has failed in its attempts to develop a migraine drug.